- Home
- CHPG vs IRWD Comparison
CHPG vs IRWD Comparison
Compare CHPG & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPG
- IRWD
- Stock Information
- Founded
- CHPG 2024
- IRWD 1998
- Country
- CHPG United States
- IRWD United States
- Employees
- CHPG N/A
- IRWD N/A
- Industry
- CHPG
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- CHPG
- IRWD Health Care
- Exchange
- CHPG Nasdaq
- IRWD Nasdaq
- Market Cap
- CHPG 100.4M
- IRWD 111.2M
- IPO Year
- CHPG N/A
- IRWD 2010
- Fundamental
- Price
- CHPG $10.02
- IRWD $1.31
- Analyst Decision
- CHPG
- IRWD Buy
- Analyst Count
- CHPG 0
- IRWD 5
- Target Price
- CHPG N/A
- IRWD $4.94
- AVG Volume (30 Days)
- CHPG 4.0K
- IRWD 1.4M
- Earning Date
- CHPG 07-23-2025
- IRWD 08-07-2025
- Dividend Yield
- CHPG N/A
- IRWD N/A
- EPS Growth
- CHPG N/A
- IRWD N/A
- EPS
- CHPG N/A
- IRWD N/A
- Revenue
- CHPG N/A
- IRWD $308,519,000.00
- Revenue This Year
- CHPG N/A
- IRWD N/A
- Revenue Next Year
- CHPG N/A
- IRWD N/A
- P/E Ratio
- CHPG N/A
- IRWD N/A
- Revenue Growth
- CHPG N/A
- IRWD N/A
- 52 Week Low
- CHPG $9.81
- IRWD $0.53
- 52 Week High
- CHPG $10.24
- IRWD $5.15
- Technical
- Relative Strength Index (RSI)
- CHPG N/A
- IRWD 72.16
- Support Level
- CHPG N/A
- IRWD $1.22
- Resistance Level
- CHPG N/A
- IRWD $1.37
- Average True Range (ATR)
- CHPG 0.00
- IRWD 0.09
- MACD
- CHPG 0.00
- IRWD 0.02
- Stochastic Oscillator
- CHPG 0.00
- IRWD 84.21
About CHPG ChampionsGate Acquisition Corporation Class A Ordinary Share
Championsgate Acquisition Corp is a blank check company.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.